B-intervention	0	11	Cryotherapy
O	12	15	for
O	16	19	the
O	20	30	prevention
O	31	33	of
O	34	40	weekly
O	41	51	paclitaxel
O	51	52	-
O	52	59	induced
B-condition	60	70	peripheral
I-condition	71	78	adverse
I-condition	79	85	events
O	86	88	in
O	89	95	breast
O	96	102	cancer
O	103	111	patients
O	111	112	.

O	113	117	This
O	118	128	randomized
O	129	134	phase
O	135	137	II
O	138	143	study
O	144	147	was
O	148	157	conducted
O	158	160	to
O	161	172	investigate
O	173	176	the
O	177	185	efficacy
O	186	188	of
O	189	200	cryotherapy
O	201	203	in
O	204	214	preventing
B-condition	215	225	peripheral
I-condition	226	236	neuropathy
O	237	240	and
B-condition	241	255	dermatological
I-condition	256	263	adverse
I-condition	264	270	events
O	271	273	in
B-eligibility	274	280	breast
I-eligibility	281	287	cancer
I-eligibility	288	296	patients
I-eligibility	297	304	treated
I-eligibility	305	309	with
I-eligibility	310	316	weekly
I-eligibility	317	327	paclitaxel
O	327	328	.

O	329	337	Patients
O	338	345	treated
O	346	350	with
O	351	353	12
O	354	360	weekly
O	361	366	doses
O	367	369	of
O	370	380	paclitaxel
O	381	384	for
O	385	391	breast
O	392	398	cancer
O	399	403	were
O	404	414	randomized
O	415	416	(
O	416	417	1
O	417	418	:
O	418	419	1
O	419	420	)
O	421	425	into
O	426	427	a
O	428	439	cryotherapy
O	440	442	or
B-control	443	450	control
I-control	451	456	group
O	456	457	.

O	458	461	The
O	462	469	primary
O	470	478	endpoint
O	479	482	was
O	483	486	the
B-outcome-Measure	487	497	percentage
I-outcome-Measure	498	500	of
I-outcome-Measure	501	509	patients
I-outcome-Measure	510	514	with
I-outcome-Measure	515	516	a
I-outcome-Measure	517	523	marked
I-outcome-Measure	524	532	decrease
I-outcome-Measure	533	535	in
I-outcome-Measure	536	539	the
I-outcome-Measure	540	550	Functional
I-outcome-Measure	551	561	Assessment
I-outcome-Measure	562	564	of
I-outcome-Measure	565	571	Cancer
I-outcome-Measure	572	579	Therapy
I-outcome-Measure	579	580	-
I-outcome-Measure	580	593	Neurotoxicity
I-outcome-Measure	594	595	(
I-outcome-Measure	595	599	FACT
I-outcome-Measure	599	600	-
I-outcome-Measure	600	603	NTX
I-outcome-Measure	603	604	)
I-outcome-Measure	605	610	score
O	610	611	.

O	612	615	The
O	616	625	secondary
O	626	635	endpoints
O	636	640	were
B-outcome-Measure	641	648	Patient
I-outcome-Measure	649	662	Neurotoxicity
I-outcome-Measure	663	676	Questionnaire
I-outcome-Measure	677	678	(
I-outcome-Measure	678	681	PNQ
I-outcome-Measure	681	682	)
I-outcome-Measure	682	683	,
I-outcome-Measure	684	690	Common
I-outcome-Measure	691	702	Terminology
I-outcome-Measure	703	711	Criteria
I-outcome-Measure	712	715	for
I-outcome-Measure	716	723	Adverse
I-outcome-Measure	724	729	Event
I-outcome-Measure	730	731	(
I-outcome-Measure	731	736	CTCAE
I-outcome-Measure	736	737	)
I-outcome-Measure	738	741	for
I-outcome-Measure	742	752	peripheral
I-outcome-Measure	753	763	neuropathy
I-outcome-Measure	763	764	,
I-outcome-Measure	765	768	and
I-outcome-Measure	769	773	FACT
I-outcome-Measure	773	774	-
I-outcome-Measure	774	780	Taxane
I-outcome-Measure	781	786	score
O	786	787	.

B-total-participants	788	793	Forty
I-total-participants	793	794	-
I-total-participants	794	798	four
O	799	807	patients
O	808	812	were
O	813	821	randomly
O	822	830	assigned
O	831	833	to
O	834	837	the
O	838	849	cryotherapy
O	850	851	(
O	851	852	n
O	853	854	=
B-intervention-participants	855	857	22
O	857	858	)
O	859	861	or
O	862	869	control
O	870	876	groups
O	877	878	(
O	878	879	n
O	880	881	=
B-control-participants	882	884	22
O	884	885	)
O	885	886	.

O	887	890	The
B-outcome	891	901	percentage
I-outcome	902	904	of
I-outcome	905	913	patients
I-outcome	914	918	with
I-outcome	919	920	a
I-outcome	921	927	marked
I-outcome	928	936	decrease
I-outcome	937	939	in
I-outcome	940	944	FACT
I-outcome	944	945	-
I-outcome	945	948	NTX
I-outcome	949	955	scores
O	956	959	was
O	960	973	significantly
O	974	979	lower
O	980	982	in
O	983	986	the
O	987	998	cryotherapy
O	999	1004	group
O	1005	1009	than
O	1010	1012	in
O	1013	1016	the
O	1017	1024	control
O	1025	1030	group
O	1031	1032	(
B-iv-bin-percent	1032	1034	41
O	1035	1037	vs
O	1037	1038	.
B-cv-bin-percent	1039	1041	73
I-cv-bin-percent	1041	1042	%
O	1042	1043	,
O	1044	1045	p
O	1046	1047	=
O	1048	1049	0
O	1049	1050	.
O	1050	1052	03
O	1052	1053	)
O	1053	1054	.

O	1055	1058	The
B-outcome	1059	1068	incidence
I-outcome	1069	1071	of
I-outcome	1072	1077	CTCAE
I-outcome	1078	1083	grade
I-outcome	1084	1085	â‰¥
I-outcome	1086	1087	2
I-outcome	1088	1095	sensory
O	1096	1097	(
O	1097	1098	p
O	1099	1100	=
O	1101	1102	0
O	1102	1103	.
O	1103	1106	001
O	1106	1107	)
O	1108	1111	and
B-outcome	1112	1117	motor
I-outcome	1118	1128	peripheral
I-outcome	1129	1139	neuropathy
O	1140	1141	(
O	1141	1142	p
O	1143	1144	=
O	1145	1146	0
O	1146	1147	.
O	1147	1149	01
O	1149	1150	)
O	1150	1151	,
O	1152	1155	and
B-outcome	1156	1159	PNQ
I-outcome	1160	1165	grade
I-outcome	1166	1167	D
I-outcome	1168	1170	or
I-outcome	1171	1177	higher
I-outcome	1178	1181	for
I-outcome	1182	1189	sensory
I-outcome	1190	1200	peripheral
I-outcome	1201	1211	neuropathy
O	1212	1213	(
O	1213	1214	p
O	1215	1216	=
O	1217	1218	0
O	1218	1219	.
O	1219	1221	02
O	1221	1222	)
O	1222	1223	,
O	1224	1227	and
B-outcome	1228	1236	decrease
I-outcome	1237	1239	in
I-outcome	1240	1243	the
I-outcome	1244	1248	FACT
I-outcome	1248	1249	-
I-outcome	1249	1255	Taxane
I-outcome	1256	1261	score
O	1262	1263	(
O	1263	1264	p
O	1265	1266	=
O	1267	1268	0
O	1268	1269	.
O	1269	1271	02
O	1271	1272	)
O	1273	1277	were
O	1278	1282	also
O	1283	1296	significantly
O	1297	1302	lower
O	1303	1305	in
O	1306	1309	the
O	1310	1321	cryotherapy
O	1322	1327	group
O	1328	1332	than
O	1333	1335	in
O	1336	1339	the
O	1340	1347	control
O	1348	1353	group
O	1353	1354	.

O	1355	1360	There
O	1361	1365	were
B-outcome	1366	1368	no
I-outcome	1369	1376	serious
I-outcome	1377	1381	side
I-outcome	1382	1389	effects
O	1390	1400	associated
O	1401	1405	with
O	1406	1417	cryotherapy
O	1417	1418	.

O	1419	1430	Cryotherapy
O	1431	1433	is
O	1434	1436	an
O	1437	1446	effective
O	1447	1455	approach
O	1456	1459	for
O	1460	1470	prevention
O	1471	1473	of
O	1474	1484	peripheral
O	1485	1495	neuropathy
O	1496	1499	and
O	1500	1514	dermatological
O	1515	1522	adverse
O	1523	1529	events
O	1530	1532	in
O	1533	1539	breast
O	1540	1546	cancer
O	1547	1555	patients
O	1556	1563	treated
O	1564	1568	with
O	1569	1575	weekly
O	1576	1586	paclitaxel
O	1586	1587	.
